Acta Paediatrica | 2019
A mini‐review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophy
Abstract
Ataluren has been approved for treating nonsense mutation Duchenne muscular dystrophy (nmDMD), and there are currently discussions concerning drug access and applications beyond the development programme. This study provides an overview of nmDMD and ataluren, stipulates clinical rules for treatment initiation and discontinuation and proposes a model for the implementation of orphan drugs in clinical practice in Sweden.